GET DAILY SIGNALSAbbVie (ABBV): Analyst Targets Point to +11.6% Upside Toward $325
Key Takeaways
- The central price target used here is $325, the arithmetic mean of eight verified analyst targets that sit above the current share price.
- ABBV last closed near $291, meaning the stock would need to rise roughly 11.6% to reach $325.
- The overall mean of all tracked targets is lower—around $306 to $310—with a wide range from roughly $237 to $350, reflecting genuine disagreement on the Street.
- The strongest supports are double-digit growth in immunology drugs Skyrizi and Rinvoq, a strengthening neuroscience franchise, and encouraging early 2027 commentary.
- The biggest risks are ongoing Humira erosion, competition in immunology and oncology, and an elevated valuation after a strong run.
- For more on the ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these additional pages.
- Explore Trending AI Robots to see how AI-driven tools are tracking opportunities across the market.
Analyst Price Targets and Consensus View
AbbVie Inc. is a global biopharmaceutical company whose portfolio spans immunology, oncology, neuroscience, and aesthetics. Because the broad average of all current analyst targets implies only a mid-single-digit premium to the share price, the $325 figure here is calculated as the mean of the verified targets that remain above the latest market price, in line with standard practice for a meaningful upside question.
Eight recent above-price targets were reviewed, including Morgan Stanley at $346 (Overweight, early November), Wells Fargo and BMO Capital each at $340, Cantor Fitzgerald at $325, Guggenheim at $322, Argus at $320, Freedom Capital Markets at $315, and Piper Sandler at $303. Their average rounds to $325. For context, the overall mean of all valid targets is roughly $306 to $310, and the full range spans from about $237 to $350, indicating that while most analysts are constructive, a meaningful minority remain cautious. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent actions skew bullish. Wolfe Research and Erste Group both upgraded the stock to Buy-equivalent ratings, while Morgan Stanley, Wells Fargo, Leerink Partners, and others lifted targets after third-quarter results. Analysts consistently cite Skyrizi and Rinvoq momentum, the neuroscience franchise, and a maturing pipeline as the core reasons behind higher targets.
Current Market Position and Path Toward the Target
ABBV last traded near $291, within sight of its 52-week high around $303. Reaching $325 would require a gain of about 11.6%—a modest move by equity-market standards, but still a meaningful step after the stock's already-strong rally of roughly 27% year to date.
The path would most plausibly run through continued execution in immunology and neuroscience. Third-quarter revenue grew about 10% year over year to roughly $17.4 billion, and management's initial 2027 commentary was described by Morgan Stanley as encouraging. A forward P/E near 18.5x also suggests the market is not yet pricing in aggressive multiple expansion, even though the trailing P/E is elevated following the recent earnings recovery.
What Could Support a Move Toward the Target
Skyrizi and Rinvoq continue to deliver double-digit growth and are offsetting the long-anticipated decline of Humira as its exclusivity erodes. Neuroscience assets such as Vraylar, Ubrelvy, and Qulipta add diversification, while strategic deals—including the roughly $10 billion Apogee acquisition and smaller immunology and migraine collaborations—extend the pipeline. A forward valuation near the low end of large-cap pharma peers and a dividend yield around 2.5% provide additional ballast for the thesis.
What Could Prevent the Target From Being Reached
The principal obstacles are competitive and valuation-related. Humira's erosion will continue to weigh on legacy revenue, and competitors are advancing in immunology and oncology, including pressure on Imbruvica. The trailing P/E above 50x reflects a rich recovery multiple that leaves little room for disappointment. Pipeline setbacks—such as underwhelming Phase 3 data for the hidradenitis suppurativa candidate lutikizumab—and U.S. drug-pricing negotiations under the Inflation Reduction Act also represent concrete downside risks that analysts themselves flag.
Technical Levels and Market Structure
The stock's 52-week high near $303 marks the nearest resistance zone, and a decisive move through that level would be a precondition for sustained progress toward $325. The $300 round-number level carries psychological weight after the recent run. On the downside, the $280 area and the mid-$260s represent prior consolidation zones that could act as support. The long-term trend remains higher, but the proximity to all-time highs raises the bar for near-term follow-through.
Time Horizon and What Investors Should Monitor
Most analyst price targets reflect a roughly 12-month research horizon, though individual firms use different valuation frameworks and timelines. Investors should watch fourth-quarter and full-year earnings, updated 2027 guidance, Skyrizi and Rinvoq prescription trends, FDA decisions on pipeline programs, and any further M&A activity. Shifts in analyst estimates and target revisions will be among the clearest signals of whether the $325 level remains within reach.
Using AI Daily Buy/Sell Signals in Practice
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single indicator, the system synthesizes multiple data streams to flag shifting trends as they develop. Traders and investors can use these signals to discover new opportunities, monitor existing positions, and spot changing market dynamics more efficiently than manual screening alone. For anyone tracking a large-cap name like ABBV, combining these AI signals with fundamental research can add a useful technical layer to the decision-making process. In my view, this approach has helped me stay objective when reviewing names with wide target ranges.
Final Assessment
Can ABBV reach $325? The question is reasonable: that level sits about 11.6% above the latest price and represents the average of the analyst targets that remain above the current quote. Support comes from accelerating immunology and neuroscience growth, a maturing pipeline, and a still-reasonable forward valuation. The counterweights are Humira erosion, intensifying competition, an elevated trailing multiple, and genuine analyst disagreement reflected in a target range spanning roughly $237 to $350. Whether the stock ultimately reaches $325 will depend on execution and on how the market weighs pipeline optionality against competitive and valuation risk—no outcome is guaranteed.
Exploring Tickeron AI Tools for Deeper Analysis
I often turn to Tickeron’s suite of AI tools when evaluating names like this one. The AI Screener helps quickly compare fundamentals across peers, while the AI Trend Prediction Engine and AI Real Time Patterns add technical context that complements traditional research. These resources have become a regular part of my process for spotting confirmation or red flags without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABBV saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for ABBV moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 69 similar instances where the indicator exited the overbought zone. In 35 of the 69 cases the stock moved lower. This puts the odds of a downward move at 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 20 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement